Bio Path Holdings Inc (BPTH)

[make it happen]

Profitability
Profit Margin 0.00%
Operating Margin 0.00%

Management Effectiveness
Return on Assets -25.12%
Return on Equity -42.71%

Cash Flow Statement
Operating Cash Flow -9.17M
Levered Free Cash Flow -5.47M

[make it happen]

Only phase 1. With 6 patients... Every old pop, drops for days.

[INFINITI]

Looks to run here got in $$$$

[Warrens]

Hopefully we run tomorrow

[Warrens]

Starting to look up here

[ClayTrader]

* * $BPTH Video Chart 04-05-2021 * *

Link to Video - click here to watch the technical chart video

[Dubster watching]

Analyst Actions: Roth Capital Starts Bio-Path Holdings at Buy With $13 Price Target

[Iron heart]

Nice call, thanks!

BTW: Gave you membermark #268

Regards Ih

[Stock_Barber]

As I said on the 10th when it was $12+...

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161702058

[Roadtojourney]

Turn out to be a pos pump and dump imo

[Paullee]

round trip is about complete

[Roadtojourney]

Pump and dump pos imo

[ClayTrader]

* * $BPTH Video Chart 02-10-2021 * *

Link to Video - click here to watch the technical chart video

[Stock_Barber]

Anyone know a broker that will let you short this?

I virtually never short stocks, but this is a no-brainer!

[Hercules1]

$BPTH:


it can hit $30 after hours today.



there are damn no shares left to be had.


shorts are going to get destroyed.

[NicksterPDX]

Well, it's 3 of them..... took in some profits at $22 to $23 per share this morning. Glad I did, now it's in the $16 range. With that said, this reminds me of what happened 2 years ago in March when over a 3 day trading period, the stock shot up and down and was a perfect day trading stock for a time! It hit a high of nearly $80.00 and would have some $20 to $30 swings in a single day..... made some very GOOD money that 3 days. I'd love to see it hit those highs again. I have my remaining shares set for a $50.00 sell (for the day). Don't know if it's gonna hit that today. Keep an eye on it.

[cfoofme]

Thanks. Must be the best patent they have ever had

[NicksterPDX]

BPTH receives 3rd patent!

Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology

[cfoofme]

Wow! Up over $10 with 23 mil vol. What's happening here?

[jonny_red]

Looking for that power bounce today on BPTH

[jonny_red]

The roof is about to blow off $BPTH

[zino]

Micro-Float...Bought some today 3.83...Glta

[mik1234]

Awesome $

[sanderburwil]

Tomorrow will be INSANE

[mik1234]

$BPTH to da moon $

[blairsoldman]

Great, they have started Phase 1 of BP 2001. The web site says:

BP1002 (Liposomal Bcl2 Antisense)

Bio-Path is planning to initiate a Phase 1 clinical trial of BP1002 in patients with follicular lymphoma, the most common form of non-Hodgkin’s lymphoma (NHL) in 2017.

so they are only 3 3/4 years behind schedule. Meanwhile PN is taking a huge salary drawing down the limited funds.

[alex1940]

The proxy is out and includes a shareholder resolution relating to the CEO

[SloDan]

Hey NicksterPDX, BPTH isn't going to FLY until they get rid of their CEO Peter Nielsen. Peter is content to pull down 500K a yr plus. Peter could care less about Joe Q Public shareholders. Peter is all about KNOBBING with the INSTITUTIONAL INVESTORS. 2018 & 2019 are proof of that.

[NicksterPDX]

OK, this roller coaster ride is giving me stomach topsie turvies! What give BPTH? When you gonna fly with your good news?

[ClayTrader]

* * $BPTH Video Chart 10-22-2020 * *

Link to Video - click here to watch the technical chart video

[whytestocks]

Breaking News: $BPTH 3 Penny Stocks To Watch Right Now After Big Corporate News

Are These 3 Penny Stocks On Your Watch List Right Now? Something almost all traders look for when it comes to trading penny stocks is a catalyst. They like to know the reason why certain stocks are moving the way they are. This might be a sector-related catalyst. It might also be a ...

In case you are interested BPTH - 3 Penny Stocks To Watch Right Now After Big Corporate News

[Biggeoff]

Carl Icahn took stake!

[whytestocks]

Breaking News: $BPTH Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers

HOUSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that...

In case you are interested BPTH - Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers

[blairsoldman]

Whoopy ding. Now if we could see what the hell progress they have made since 2016 things might look even better.

[Paullee]

Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers
Bio-Path Holdings, Inc.
Thu, October 22, 2020, 7:00 AM EDT
Growing Patent Estate Creates Value and Supports Key Combination Therapies

HOUSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s lead product candidate, prexigebersen, in combination with either a cytidine analogue, such as decitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib and nilotinib. Prexigebersen is a liposomal formulation containing the antisense oligodeoxynucleotide targeting growth factor receptor-bound protein 2 (Grb2).

The new patent, titled, “Combination Therapy with Liposomal Antisense Oligonucleotides,” (based on Application No. 16/333,221), will provide broad protection for application of prexigebersen in the treatment of a variety of cancers in combination with front-line therapies.

“This further strengthens our intellectual property portfolio and complements already granted patents. Our growing patent estate continues to be a valuable asset for Bio-Path as it provides protection not only for our core product portfolio and research efforts but now also offers broad protection in combination with established front-line therapies,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

“Bio-Path is currently in an ongoing Phase 2 clinical trial of prexigebersen in combination with decitabine as a treatment for acute myeloid leukemia (AML), and this new patent protects the unique therapy combination and supports our ongoing investment in this program to bring a new treatment option to patients with AML who have limited treatment options,” added Mr. Nielsen.

[Awl416]

News

[makingitnow]

This Patent news they got today. I am looking for advice from more of a biotec kinda guy. How relevant is it? with the news Presenting that came out the 9th seems like they may have somthing going on positive. Thoughts?

[SloDan]

WTH - Haven't we heard all this before?? News Flash Peter, we are 8 1/2 months into 2020, so why all the 2019 Blabber.

[blairsoldman]

The press release references the web site. This contains the wonderfully hopeful statements that kept us happy four years ago, before the disillusionment and the 200:1 RSS. Remember when we loved reading:
++++++++++++++++++++++++
Current Development Status

- Based on successful results of a Phase 1 clinical trial, Bio-Path has initiated a Phase 2 program in AML, comprised of two clinical trials of BP1001 in combination with the first-line standard-of-care chemotherapy, low dose Ara C (LDAC):

The first has been initiated in 54 newly diagnosed AML patients who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
A second study in relapsed and refractory AML patients is expected to be initiated in 2017.

- Prexigebersen has also completed a Phase 1 clinical trial in patients with CML and expects to initiate enrollment before the end of 2016 for the dose-determining segment of a Phase 2 trial of prexigebersen in combination with first-line standard-of-care for CML, dasatinib.

+++++++++++++++
WOW. THe expectations for 2016 and 2017.
WHAT HAPPENED???

WTF has been done in the four years since that "Current Status" was written?

Where have they spent all that money?

Presentations to try to get new investment are not what is needed. What is needed are presentations by credible scientists on what has been done in the last four years and what results have been obtained.

[blairsoldman]

So PN is going on the road again after ?how many years? to try to re kick start this scam. He will surely drone on in his own inimical boring manner over mostly three year old results. How many decades can he keep this up?

http://www.globenewswire.com/news-release/2020/09/09/2090818/0/en/Bio-Path-Holdings-to-Present-at-the-H-C-Wainwright-22nd-Annual-Global-Investment-Conference.html

[SJSTOCKSHARK]

BPTH better get move on with the trials. The only have enough cash to last another year.

[benchman]

Unfortunately, today was not a repeat performance

[ClayTrader]

* * $BPTH Video Chart 08-21-2020 * *

Link to Video - click here to watch the technical chart video

[kingsplay]

This sock has made me a lot of money in the past. I saw this stock go from $2 to $72 in less than 2 weeks. The day it ran to $72 it opened at $18 closed at $38. Volume was 36,000,000 shares traded. I made a really nice return on my money that week. This is a stock that you buy what you can afford and sale small partials as it gains momentum. I bought back in in the 3's hoping for another amazing run. Fundamentally there is a good chance this company could stumble upon a successful treatment for cancer. They are connected to MD Anderson hospital here in Houston.

[Paullee]

yeah, but at this volume with so little movement, it doesn't make sense

[whytestocks]

JUST IN: $BPTH Are Penny Stocks Worth It? 3 On The Rise This Week

Penny Stocks To Watch Before The Weekend Are penny stocks worth it? It’s not a rhetorical question and one I’m sure people ask themselves every time they look at small-cap stocks . I’m sure that if you’re reading this, you’ve got some interest in making ...

Got this from BPTH - Are Penny Stocks Worth It? 3 On The Rise This Week

[benchman]

A lot of buying and selling in the same day. See this article below:

https://www.investopedia.com/ask/answers/05/sharestradedoutstanding.asp

[Paullee]

How can they do 4.2 mil shs at noon, when there is only 3.7 mil shs o/s

[benchman]

I'll take $72 $BPTH

[kingsplay]

I wonder if this is going to repeat last years run? Ity started off the same way. Large purchases, then huge short volume followed by huge buys again forceing a short squeeze that ran the price to $72. I could sure use the money.